Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Letters17 July 2018Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune DiseaseNoha Abdel-Wahab, MD, PhD, Mohsin Shah, MD, Maria A. Lopez-Olivo, MD, PhD, and Maria E. Suarez-Almazor, MD, PhDNoha Abdel-Wahab, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Mohsin Shah, MDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, Maria A. Lopez-Olivo, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this author, and Maria E. Suarez-Almazor, MD, PhDUniversity of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L18-0209 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Because our article was a systematic review of reported cases in the literature, we were limited by the quality of information available in the original articles. Insufficient reporting of certain data was acknowledged. As such, we did not report information on the extent of tumor mass at the time of adverse events. We have included only reports describing patients with an established diagnosis of autoimmune disease before initiation of checkpoint inhibitor (CPI) therapy for concomitant cancer. We based our determination on the reports of the authors of the original articles, and most of these autoimmune diseases—such as psoriasis, ...References1. Fam AG. Paraneoplastic rheumatic syndromes. Baillieres Best Pract Res Clin Rheumatol. 2000;14:515-33. [PMID: 10985984] CrossrefMedlineGoogle Scholar2. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662-70. [PMID: 25136782] doi:10.1038/nrrheum.2014.138 CrossrefMedlineGoogle Scholar3. Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, et al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785-92. [PMID: 28068177] doi:10.1200/JCO.2015.66.1389 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Texas MD Anderson Cancer Center, Houston, Texas (N.A., M.S., M.A.L., M.E.S.)Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M17-2073. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUse of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Noha Abdel-Wahab , Mohsin Shah , Maria A. Lopez-Olivo , and Maria E. Suarez-Almazor Use of Immune Checkpoint Inhibitors in the Treatment of Patients With Cancer and Preexisting Autoimmune Disease Yasuo Oshima , Noboru Hagino , Masumi Hara , and Takashi Ohfuji Metrics Cited byManagement of Cancer-Associated MyositisTreatment of rheumatic adverse events of cancer immunotherapyRespiratory ComplicationsBone Marrow–Liver–Thymus ( BLT ) Humanized Mice as a Tool to Assess Checkpoint Inhibitor Adverse EventsImmune Checkpoint Blockade and Skin Toxicity PathogenesisPulmonary Complications of Lung Cancer TherapiesRheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer ImmunotherapyReal-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint InhibitorsImmune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and ManagementPyroptosis-Related Gene Signatures Can Robustly Diagnose Skin Cutaneous Melanoma and Predict the PrognosisCheckpoint inhibitor therapy for metastatic triple-negative breast cancerSafety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease A Cohort StudyMonique K. van der Kooij, MD, Karijn P.M. Suijkerbuijk, MD, PhD, Maureen J.B. Aarts, MD, PhD, Franchette W.P.J. van den Berkmortel, MD, PhD, Christian U. Blank, MD, PhD, Marye J. Boers-Sonderen, MD, PhD, Jesper van Breeschoten, MSc, Alfonsus J.M. van den Eertwegh, MD, PhD, Jan Willem B. de Groot, MD, PhD, John B.A.G. Haanen, MD, PhD, Geke A.P. Hospers, MD, PhD, Djura Piersma, MD, PhD, Rozemarijn S. van Rijn, MD, PhD, Albert J. ten Tije, MD, PhD, Astrid A.M. van der Veldt, MD, PhD, Gerard Vreugdenhil, MD, PhD, Michiel C.T. van Zeijl, MD, Michel W.J.M Wouters, MD, PhD, Olaf M. Dekkers, MD, PhD, and Ellen Kapiteijn, MD, PhDNeurological Complications of Targeted Therapies and Immunotherapies for CancerInternational Consensus Guidance for Management of Myasthenia GravisMarked improvement of oral intake with nivolumab monotherapy in a patient with microsatellite instability‐high gastric cancer with insufficient oral intakeSarcoidosisCheckpoint inhibitors: In
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma
Weber, J. S., Hodi, F. S., Wolchok, J. D., Topalian, S. L., Schadendorf, D., Larkin, J., Sznol, M., Long, G. V., Li, H., Waxman, I. M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.1389 · Cited by 1,158
Cited by
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
Martins, F., Sofiya, L., Sykiotis, G. P., Lamine, F., Maillard, M., Fraga, M., Shabafrouz, K., Ribi, C., Cairoli, A., Guex-Crosier, Y., et al. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0218-0 · Cited by 2,314
International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update
Narayanaswami, P., Sanders, D. B., Wolfe, G., Benatar, M., Cea, G., Evoli, A., Gilhus, N. E., Illa, I., Kuntz, N. L., Massey, J., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011124 · Cited by 813
Safa, H., Johnson, D. H., Trinh, V. A., Rodgers, T. E., Lin, H., Suarez-Almazor, M. E., Fa’ak, F., Saberian, C., Yee, C., Davies, M. A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0774-y · Cited by 312
Self-citationHaanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Frohne, C. C., Llano, E. M., Perkovic, A., Cohen, R. D., & Luke, J. J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0484-x · Cited by 171
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33
Metadata
- Authors
- Abdel-Wahab, N., Shah, M., Lopez-Olivo, M. A., & Suarez-Almazor, M. E.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2018-07-17
- Volume
- 169
- Issue
- 2
- Pages
- 133-134
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2883350403
- Cited by
- 63
- References
- 1
- FWCI
- 3.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.